NCT02507687
Brief summary
This study will evaluate the intraocular pressure-lowering effect and safety of Bimatoprost SR compared with selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension who are not adequately managed with topical IOP-lowering medication.
Interventional study
- 1
- 2
- 3
- 4
Age:
18 Years and older.
Inclusion Criteria:
Inclusion Criteria:
- Diagnosis of either Open-Angle Glaucoma or Ocular Hypertension in each eye that
require IOP lowering treatment.
Exclusion Criteria:
Exclusion Criteria:
- Eye surgery (including cataract surgery) and or eye laser surgery within the past 6
months.
- Previous use of commercially available Bimatoprost SR; concurrent enrollment in
another Allergan Bimatoprost SR study; or previous enrollment in which an implant was
received.